Prestige Healthcare (PBH) Q2 2027 Earnings Call Transcript

Prestige Consumer Healthcare reported fiscal Q2 revenue of $336.3 million, up 22.7% including Breathe Right and LaCorium, while organic revenue declined 1.6%; adjusted diluted EPS rose about 6% to $1.13. Management cut fiscal 2027 revenue guidance to $1.28 billion–$1.29 billion from $1.29 billion–$1.315 billion and adjusted EPS guidance to $4.48–$4.55 from $4.55–$4.65, citing Clear Eyes production volatility and higher interest expense. It expects less than $20 million in Clear Eyes sales for the year, at least $265 million in adjusted free cash flow, and a year-end leverage ratio near 4x, with cash flow directed toward debt reduction.

Analysis

The key risk is not the current-year revenue loss from Clear Eyes alone; it is whether Pillar5 can turn a supply constraint into a reliable competitive advantage. A small brand can create outsized volatility when there is no safety stock, while a prolonged recovery would undermine confidence in management’s broader manufacturing and integration execution. Conversely, if competing redness-relief suppliers remain constrained and PBH achieves consistent output, the company could capture category demand without relying solely on new product launches. That upside is conditional: management’s favorable inspection commentary does not establish repeatable production capability.

Near term (days to 1–3 months), expect the Q3 comparison, weak Clear Eyes availability, and peak marketing spend to keep estimate risk skewed down. The larger portfolio and acquired brands provide some offset, but acquisition growth is less valuable to equity holders while interest costs and roughly fourfold leverage constrain capital allocation. The stated free-cash-flow deleveraging path is important, but depends on delivery of cash generation and not just adjusted earnings.

Over 6–18 months, stable Pillar5 output could unlock share gains amid industry shortages; another interruption would extend the guidance-reset cycle and weaken the recovery thesis. The contrarian angle is that Clear Eyes is a small share of sales, so the headline cut may overstate the damage to the core portfolio—but that does not make the 2028 recovery credible yet. Verify channel consumption versus shipments, facility output and service levels, and net-debt reduction before underwriting that upside.

Key Decisions for Investors

• Keep PBH neutral-to-underweight rather than adding on the category-shortage narrative; reassess after Q3 and the next production update. The upside case needs evidence of repeatable Pillar5 output, not simply demand or management confidence.
• For existing PBH exposure, consider a defined-risk put spread through the next earnings/production update rather than an outright short: downside catalysts include another Clear Eyes shortfall or weaker free cash flow, while persistent third-party supply disruption could produce a sharp recovery. Size against the possibility that the brand’s small revenue contribution limits fundamental downside.
• Track quarterly Clear Eyes availability and shipments against channel consumption, adjusted free cash flow versus the at-least-$265 million plan, and net debt/leverage. Falsify the recovery thesis if production again misses the company’s stated back-half assumptions or debt reduction stalls; strengthen it only after sustained supply normalization.
• Monitor competitor shelf availability, especially redness-relief and multisymptom products from Bausch + Lomb and other suppliers. If shortages persist while PBH restores reliable supply, revisit a long PBH position; if industry supply normalizes before PBH stabilizes Pillar5, the prospective share-capture advantage fades.